Lyo-Ready Genotyping Direct qPCR Urine has been optimized to provide highly specific allelic discrimination as demonstrated by excellent cluster separation, even in the presence of PCR inhibitors found in crude human urine samples. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation and comprise the major part of phenotype diversity between individuals. SNPs can be responsible for both resistance or susceptibility to a certain disease and once individual SNPs have been identified by sequencing, they can be used for pharmacogenetics, in evaluating and predicting a patient’s response to treatment and risk of adverse events, or for diagnostics, such as in cancer screening. Clinical screening of SNPs requires large-scale multiplexed genotyping, which traditionally relies on DNA extraction from complex samples such as blood, to achieve sensitive DNA amplification. However, blood collection is invasive and requires a professional, urine on the other hand is an extremely non-invasive process, that is safe, less expensive and easy to do at home, making it ideal for large population or frequent sampling, particularly when children or people that will not comply with blood collections.
Meridian’s Lyo-Ready Genotyping Direct qPCR Urine is a 4x inhibitor-resistant mix designed for highly specific and sensitive amplification for genotyping sequence variants, even in the presence of PCR inhibitors found in crude urine samples, to give exceptional cluster resolution with clear allele discrimination, even with challenging SNP targets. Furthermore, it can be used in a liquid or lyophilized format to create ambient-temperature stable assays, making it ideal for point-of-care (POC) devices.
This product has met the following criteria to qualify for the following awards: